FORM	4
------	---

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative

UNITED STATES S	ECURITIES AND	EXCHANGE	COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSH
--

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL								
OMB Number: 3235-0287								
Estimated average burden								
hours per response:	0.5							

defense conditions of Rule 10b5-1(c) See Instruction 10. 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person\* Singular Genomics Systems, Inc. [ OMIC ] (Check all applicable) Spaventa Andrew Director 10% Owner Officer (give title Other (specify 1 3. Date of Earliest Transaction (Month/Day/Year) below) below) (Last) (First) (Middle) 09/15/2024 Chief Executive Officer 3010 SCIENCE PARK ROAD 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable (Street) Line) SAN DIEGO CA 92121 1 Form filed by One Reporting Person Form filed by More than One Reporting Person (Citv) (State) (Zip)

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(1130.4)
Common Stock	09/15/2024		M <sup>(1)</sup>		487	A	(1)	812(2)	D	
Common Stock	09/15/2024		<b>S</b> <sup>(3)</sup>		175	D	\$12.381	637(2)	D	
Common Stock	09/15/2024		<b>G</b> <sup>(4)</sup>		312	D	\$ <mark>0</mark>	325 <sup>(2)</sup>	D	
Common Stock	09/15/2024		G <sup>(4)</sup>		312	A	\$0	140,275 <sup>(2)</sup>	I	By The Andrew K. Spaventa Living Trust dated April 9, 2014
Common Stock								85(2)	I	By Axon Holdings, LLC <sup>(5)</sup>

 
 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			( 0,	· ·		, 		<i>'</i> '	<i>,</i>		,				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Deriv Secu Acqu (A) o Disp of (D	r osed ) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		piration Date Amount of		8. Price of Derivative Security (Instr. 5)		Ownership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(6)	09/15/2024		М			487	(7)	(7)	Common Stock	487	\$0	4,860 <sup>(2)</sup>	D	

Explanation of Responses:

1. Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 2. On June 26, 2024, the Issuer effected a 1-for-30 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

3. The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted RSUs.

4. Immediately upon settlement of the vested RSUs, and following the withholding described above, the Reporting Person transferred the shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.

5. The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

6. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

7. The RSUs vest in 16 equal quarterly installments over four years measured from March 15, 2023.

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.